Lipid nanoparticles for parenteral delivery of actives.

dc.contributor.author	Joshi, MD
dc.contributor.author	Müller, RH
dc.date.accessioned	2013-07-31T13:21:57Z
dc.date.available	2013-07-31T13:21:57Z
dc.date.issued	2008
dc.identifier.citation	Eur J Pharm Biopharm. 2009 Feb;71(2):161-72. doi: 10.1016/j.ejpb.2008.09.003. Epub 2008 Sep 13.	en
dc.identifier.uri	http://www.ncbi.nlm.nih.gov/pubmed/18824097
dc.identifier.uri	http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/53047
dc.description.abstract	The present review compiles the applications of lipid nanoparticles mainly solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC) and lipid drug conjugates (LDC) in parenteral delivery of pharmaceutical actives. The attempts to incorporate anticancer agents, imaging agents, antiparasitics, antiarthritics, genes for transfection, agents for liver, cardiovascular and central nervous system targeting have been summarized. The utility of lipid nanoparticles as adjuvant has been discussed separately. A special focus of this review is on toxicity caused by these kinds of lipid nanoparticles with a glance on the fate of lipid nanoparticles after their parenteral delivery in vivo viz the protein adsorption patterns.	en
dc.language.iso	en	en
dc.publisher	University of Nairobi	en
dc.title	Lipid nanoparticles for parenteral delivery of actives.	en
dc.type	Article	en
local.publisher	Faculty of medicine	en